Spectral AI Reports Revenue Decline and Increased Net Loss in Q2 2026

Spectral AI, Inc. reported its financial results for the second quarter of 2026, revealing a decline in revenue and an increase in net loss compared to the same period in 2025. The company generated $3.5 million in research and development revenue for the three months ended June 30, 2026, a decrease of 30.4% from $5.1 million in the prior year. For the six-month period, revenue fell to $7.5 million from $11.8 million, reflecting a 36.2% decline. The decrease is attributed to a reduction in reimbursed costs under the Biomedical Advanced Research and Development Authority (BARDA) contract following the FDA's De Novo authorization of the DeepView System, which has narrowed the scope of work.

The company's net loss for the second quarter was $4.2 million, compared to a loss of $8.0 million in the same quarter of 2025. For the first half of 2026, the net loss was $7.6 million, up from $5.1 million in the prior year. The increase in losses is primarily due to higher operating expenses, which rose to $5.4 million in the second quarter from $4.4 million a year earlier. This increase was driven by higher general and administrative costs, including stock-based compensation, as well as increased selling and marketing expenses in anticipation of the upcoming commercial launch of the DeepView System.

In terms of operational developments, Spectral AI has made significant strides in its product offerings. The DeepView System received FDA De Novo classification on May 26, 2026, allowing the company to begin commercial distribution in the United States. The company has also received substantial funding from BARDA, with a total contract value of approximately $150 million, which includes a recent modification that accelerated $31.7 million for further development activities. As of June 30, 2026, the company had approximately $14.0 million in cash and cash equivalents, down from $15.4 million at the end of 2025.

Spectral AI's workforce has also expanded, with the company reporting an increase in employee headcount as it prepares for commercialization. The company is focused on enhancing its sales and marketing efforts to support the launch of the DeepView System, which is expected to generate its first commercial sales by the end of 2026. The company anticipates that the DeepView System will have two revenue streams: a software as a medical device (SaMD) model and an imaging device component, with pricing strategies tailored to different markets.

Looking ahead, Spectral AI remains optimistic about its future, although it acknowledges the challenges of transitioning from a research-focused entity to a commercial operation. The company plans to leverage its existing government contracts while also exploring additional funding opportunities to support its growth initiatives. However, management cautions that the timing and amount of future government awards may impact revenue consistency, and the company may need to raise additional capital to sustain its operations and expand beyond its current focus on burn indications.